查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930112

全球心血管藥物市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考慮因素以及未來預測（2026-2034）

Cardiovascular Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 139 Pages | 商品交期: 請詢問到貨日

價格

心血管藥物市場成長因素

全球心血管藥物市場是製藥業最成熟、最重要的細分市場之一，其成長主要受全球心血管疾病負擔日益加重的驅動。心血管疾病（CVD）仍然是全球首要死因，高血壓、冠狀動脈疾病、心律不整、高血脂、心肌梗塞和中風等疾病對醫療保健系統造成了重大影響。

市場規模及預測

根據 Fortune Business Insights 預測，2025 年全球心血管藥物市場規模預估為 615.8 億美元。預計到 2026 年將成長至 639.7 億美元，到 2034 年將達到 868.5 億美元，在預測期（2026-2034 年）內複合年增長率 (CAGR) 為 3.90%。

這種穩定成長反映了心血管疾病的慢性特徵、長期藥物依賴性、疾病意識的提高以及藥物研發的持續創新。

市場概況及疾病負擔

心血管疾病 (CVD) 指的是心臟和血管的疾病，包括心臟病發作和中風等危及生命的疾病。根據世界衛生組織 (WHO) 統計，心臟病發作和中風佔心血管疾病死亡人數的五分之四。缺乏運動、不健康飲食、肥胖、吸煙、糖尿病和高血壓等生活方式因素持續加速著該疾病在全球的流行。

高風險族群通常會出現高血壓、高膽固醇、高血糖和肥胖等症狀，從而推動了對心血管藥物的長期需求。

主要市場驅動因子

心血管藥物市場的主要驅動因素之一是人們對心血管健康的日益重視以及診斷和治療率的提高。同時，持續的研發正在推出更先進、更有效的藥物療法。

由百時美施貴寶和輝瑞公司共同開發的重磅藥物，例如艾樂妥（阿哌沙班），在預防中風和心臟病方面展現出卓越的臨床療效，顯著提升了市場收入。不斷增長的未滿足治療需求，尤其是在老齡化社會中，進一步支撐了市場的持續成長。

市場區隔分析

依藥物類型劃分

依藥物類型，市場可細分為降血壓藥、降血脂藥、抗凝血藥、抗血小板藥和其他藥物。

抗凝血藥物細分市場佔主導地位，預計2026年將佔約50.44%的市場。其主導地位主要得益於高昂的藥價、廣泛的臨床應用以及艾樂妥等領先品牌的強勁銷售。抗高血壓藥物市場佔有率位居第二，但由於仿製藥的普及，其增長速度正在放緩。

依疾病分類

依疾病分類，市場可分為高血壓、高血脂、冠狀動脈疾病、心律不整和其他疾病。

高血壓市場由於其全球高發病率以及作為心臟病和中風的主要危險因素，預計到2026年將佔市場佔有率的31.04%，複合年增長率顯著。

依分銷管道分類

依分銷管道分類，市場可分為醫院藥局、零售藥局、線上藥局和其他通路。

醫院藥局領域將引領市場，預計到 2026 年將佔 46.84% 的市場佔有率，因為心血管藥物通常是在醫院確診後開立的。由於數位化和便利性的進步，預計線上藥局將擁有最高的成長率。

區域分析

預計北美將在2025年佔心血管藥物市場的主導地位，市佔率達45.16%，並在2026年創造287.8億美元的收入。光是美國市場預計到2026年就將達到266.8億美元，主要得益於高發病率和強勁的研發活動。

預計亞太地區將實現最快成長，其中日本預計到2026年將達到53.1億美元，中國預計達到37.3億美元，印度預計達到18.3億美元。歐洲預計也將保持穩定成長，這主要得益於較高的心血管疾病死亡率，尤其是在英國、法國和德國。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇

第四章：關鍵考慮因素

  • 主要國家主要心血管疾病的盛行率
  • 在開發產品分析
  • 主要產業趨勢：併購等
  • 新產品上市
  • 主要國家的監管環境
  • 主要國家的健保報銷情況
  • 新型藥物研發進展治療學

第五章 全球心血管藥物市場分析：洞察與預測（2021-2034）

  • 主要分析結果/摘要
  • 市場分析、洞察與預測：依藥物類型劃分
    • 抗高血壓藥
    • 降血脂藥
    • 抗凝血藥
    • 抗血小板藥
    • 其他
  • 市場分析、洞察與預測：依疾病劃分
    • 高血壓
    • 高血脂症
    • 冠狀動脈疾病患者
    • 心律不整
    • 其他
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美心血管藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲心血管藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國王國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太心血管藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲心血管藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東與非洲心血管藥物市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 主要的產業趨勢
  • 世界市場佔有率分析(2025年)
  • 競爭形勢儀表板
  • 主要企業的比較分析
  • 企業簡介
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Merck &Co., Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • Other Prominent Players
Product Code: FBI100379

Growth Factors of cardiovascular drugs Market

The global cardiovascular drugs market represents one of the most established and essential segments of the pharmaceutical industry, driven by the growing burden of heart and blood vessel-related disorders worldwide. Cardiovascular diseases (CVDs) remain the leading cause of mortality globally, with conditions such as hypertension, coronary artery disease, arrhythmia, hyperlipidemia, myocardial infarction, and stroke significantly impacting healthcare systems.

Market Size and Forecast

According to Fortune Business Insights, the global cardiovascular drugs market size was valued at USD 61.58 billion in 2025. The market is projected to grow to USD 63.97 billion in 2026 and further reach USD 86.85 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 3.90% during the forecast period (2026-2034).

The steady growth reflects the chronic nature of cardiovascular diseases, long-term drug dependency, increasing disease awareness, and continued innovation in drug development.

Market Overview and Disease Burden

Cardiovascular diseases are disorders of the heart and blood vessels and include life-threatening conditions such as heart attacks and strokes. According to the World Health Organization (WHO), four out of five cardiovascular disease deaths are caused by heart attacks and strokes. Lifestyle factors such as physical inactivity, unhealthy diets, obesity, smoking, diabetes, and high blood pressure continue to accelerate disease prevalence globally.

Individuals at high risk often exhibit elevated blood pressure, cholesterol, blood glucose levels, and obesity, increasing the long-term demand for cardiovascular therapeutics.

Key Market Drivers

One of the primary drivers of the cardiovascular drugs market is increased awareness of cardiovascular health, along with improved diagnosis and treatment rates. In parallel, continuous research and development (R&D) has led to the introduction of advanced and more effective drug therapies.

Blockbuster drugs such as Eliquis (apixaban), developed by Bristol-Myers Squibb Company and Pfizer Inc., have demonstrated superior clinical outcomes in preventing strokes and heart attacks, significantly boosting market revenues. The growing unmet treatment need, especially in aging populations, further supports sustained market growth.

Market Segmentation Analysis

By Drug Type

Based on drug type, the market is segmented into antihypertensive, antihyperlipidemic, anticoagulants, antiplatelet drugs, and others.

The anticoagulants segment dominates the market, accounting for an estimated 50.44% market share in 2026. This dominance is driven by high drug prices, widespread clinical use, and strong sales of leading brands such as Eliquis. The antihypertensive segment holds the second-largest share, although growth is moderated by the widespread availability of generic drugs.

By Disease Indication

By disease indication, the market is segmented into hypertension, hyperlipidemia, coronary artery disease, arrhythmia, and others.

The hypertension segment is anticipated to grow at a significant CAGR, holding a 31.04% share in 2026, supported by its high global prevalence and its role as a major risk factor for heart attacks and strokes.

By Distribution Channel

In terms of distribution, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment leads the market, accounting for 46.84% share in 2026, as cardiovascular drugs are often prescribed following hospital-based diagnosis. Online pharmacies are expected to witness the highest growth rate due to increasing digital adoption and convenience.

Regional Analysis

North America dominated the cardiovascular drugs market with a 45.16% share in 2025, generating USD 28.78 billion in revenue in 2026. The U.S. market alone is projected to reach USD 26.68 billion by 2026, driven by high disease prevalence and strong R&D activity.

The Asia Pacific region is expected to witness the fastest growth, with Japan reaching USD 5.31 billion, China USD 3.73 billion, and India USD 1.83 billion by 2026. Europe is also projected to grow steadily due to high cardiovascular mortality rates, particularly in the U.K., France, and Germany.

Competitive Landscape

The market is dominated by major pharmaceutical players such as Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, AstraZeneca, Novartis AG, and Sanofi. The industry remains mature, highly competitive, and strongly influenced by generic drug penetration.

Conclusion

In conclusion, the global cardiovascular drugs market is expected to grow steadily from USD 61.58 billion in 2025 to USD 86.85 billion by 2034, supported by rising cardiovascular disease prevalence, strong demand for anticoagulants, continuous drug innovation, and expanding healthcare access. Despite generic competition, the market will continue to remain a critical pillar of the global pharmaceutical industry due to the chronic and life-threatening nature of cardiovascular diseases.

Segmentation By Drug Type

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments Such as Mergers & Acquisitions
  • 4.4. New Product Launches
  • 4.5. The Regulatory Scenario in Key Countries
  • 4.6. Reimbursement Scenario by Key Countries
  • 4.7. Advances in R&D for Novel Therapeutics

5. Global Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Type
    • 5.2.1. Antihypertensive
    • 5.2.2. Antihyperlipidemic
    • 5.2.3. Anticoagulants
    • 5.2.4. Antiplatelet Drugs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Hypertension
    • 5.3.2. Hyperlipidemia
    • 5.3.3. Coronary Artery Disease
    • 5.3.4. Arrhythmia
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Drug Type
    • 6.2.1. Antihypertensive
    • 6.2.2. Antihyperlipidemic
    • 6.2.3. Anticoagulants
    • 6.2.4. Antiplatelet Drugs
    • 6.2.5. Others
  • 6.3. Market Analysis - By Disease Indication
    • 6.3.1. Hypertension
    • 6.3.2. Hyperlipidemia
    • 6.3.3. Coronary Artery Disease
    • 6.3.4. Arrhythmia
    • 6.3.5. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Drug Type
    • 7.2.1. Antihypertensive
    • 7.2.2. Antihyperlipidemic
    • 7.2.3. Anticoagulants
    • 7.2.4. Antiplatelet Drugs
    • 7.2.5. Others
  • 7.3. Market Analysis - By Disease Indication
    • 7.3.1. Hypertension
    • 7.3.2. Hyperlipidemia
    • 7.3.3. Coronary Artery Disease
    • 7.3.4. Arrhythmia
    • 7.3.5. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Drug Type
    • 8.2.1. Antihypertensive
    • 8.2.2. Antihyperlipidemic
    • 8.2.3. Anticoagulants
    • 8.2.4. Antiplatelet Drugs
    • 8.2.5. Others
  • 8.3. Market Analysis - By Disease Indication
    • 8.3.1. Hypertension
    • 8.3.2. Hyperlipidemia
    • 8.3.3. Coronary Artery Disease
    • 8.3.4. Arrhythmia
    • 8.3.5. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Drug Type
    • 9.2.1. Antihypertensive
    • 9.2.2. Antihyperlipidemic
    • 9.2.3. Anticoagulants
    • 9.2.4. Antiplatelet Drugs
    • 9.2.5. Others
  • 9.3. Market Analysis - By Disease Indication
    • 9.3.1. Hypertension
    • 9.3.2. Hyperlipidemia
    • 9.3.3. Coronary Artery Disease
    • 9.3.4. Arrhythmia
    • 9.3.5. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiovascular Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Drug Type
    • 10.2.1. Antihypertensive
    • 10.2.2. Antihyperlipidemic
    • 10.2.3. Anticoagulants
    • 10.2.4. Antiplatelet Drugs
    • 10.2.5. Others
  • 10.3. Market Analysis - By Disease Indication
    • 10.3.1. Hypertension
    • 10.3.2. Hyperlipidemia
    • 10.3.3. Coronary Artery Disease
    • 10.3.4. Arrhythmia
    • 10.3.5. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country/ sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Bristol-Myers Squibb Company
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. Pfizer Inc.
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Bayer AG
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Janssen Pharmaceuticals, Inc.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. AstraZeneca
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Sanofi
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Novartis AG
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Merck & Co., Inc.
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. Gilead Sciences, Inc.
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. F. Hoffmann-La Roche Ltd
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)

List of Tables

  • Table 1: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 2: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 6: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 10: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 14: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 18: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Drug Type, 2021-2034
  • Table 22: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Cardiovascular Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiovascular Drugs Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025-2034
  • Figure 3: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antihypertensive, 2021-2034
  • Figure 4: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antihyperlipidemic, 2021-2034
  • Figure 5: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Anticoagulants, 2021-2034
  • Figure 6: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Antiplatelet Drugs, 2021-2034
  • Figure 7: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 8: Global Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025-2034
  • Figure 9: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hypertension, 2021-2034
  • Figure 10: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hyperlipidemia, 2021-2034
  • Figure 11: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Coronary Artery Disease, 2021-2034
  • Figure 12: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Arrhythmia, 2021-2034
  • Figure 13: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 14: Global Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 15: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 16: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 17: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 18: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 19: Global Cardiovascular Drugs Market Forecast (US$ Mn), by Mod5, 2021-2034
  • Figure 20: Global Cardiovascular Drugs Market Value (US$ Mn), by Region, 2025-2034
  • Figure 21: North America Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 22: North America Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 23: North America Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 24: North America Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 25: North America Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 26: North America Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 27: North America Cardiovascular Drugs Market Value (US$ Mn), By Country, 2025-2034
  • Figure 28: North America Cardiovascular Drugs Market Value Share (%), By Country, 2025
  • Figure 29: Europe Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 30: Europe Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 31: Europe Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 32: Europe Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Europe Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 34: Europe Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 36: Europe Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 39: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 42: Asia Pacific Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 43: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 44: Asia Pacific Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 46: Latin America Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 47: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 48: Latin America Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 49: Latin America Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 50: Latin America Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 51: Latin America Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 52: Latin America Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 53: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Drug Type, 2025-2034
  • Figure 54: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Drug Type, 2025
  • Figure 55: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Disease Indication, 2025
  • Figure 57: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 59: Middle East & Africa Cardiovascular Drugs Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 60: Middle East & Africa Cardiovascular Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 61: Global Cardiovascular Drugs Market Share (%), By Company, 2025